PubMed Health⌕ Search

PubMed · 15500139

[Nephrotic syndrome and malignancy].

Abstract

The patients with nephrotic syndrome frequently associate with solid tumors as well as hematologic malignancies, although the presence of nephrotic syndrome in patients with malignancy is rare. The association cannot be explained by chance alone, because it occurs at a rate. Theoretically, malignancy-associated glomerulopathy should be explained by at least two clinical criteria. First, a remission of proteinuria achieves after surgical removal of tumor or disappearance of tumor by chemotherapy. Second, relapse of proteinuria occurs after recurrence of malignancy. However, pathophysiologic link which is the third important criteria has not been established between the two diseases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hiroshi Matsumoto, Yume Nagaoka. 2004. [Nephrotic syndrome and malignancy].. https://pubmed.ncbi.nlm.nih.gov/15500139/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗